Physician profile
Jorge Martinez
NPI 1508864729
$5,363.53
in general payments reported to CMS, 2019-2025
30 companies · $845 in 2025
The $845 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,435 · 2020: $478 · 2021: $264 · 2022: $444 · 2023: $800 · 2024: $1,097 · 2025: $845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,742.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,742.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,079.68 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $991.03 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $780.30 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Sanofi-Aventis U.S. LLC | $282.80 | 2019-2022 | |
| Pfizer INC. | $195.94 | 2019-2022 | |
| Mannkind Corporation | $187.59 | 2019-2023 | Afrezza |
| Amgen INC. | $184.80 | 2019-2025 | Repatha, Otezla, Repatha |
| Astellas Pharma US INC | $165.55 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $162.36 | 2022-2025 | |
| Bard Peripheral Vascular, INC. | $136.98 | 2019 | |
| Merck Sharp & Dohme LLC | $131.26 | 2019-2025 | Gardasil 9, Capvaxive, Vaxneuvance |
| Dexcom, INC. | $126.83 | 2024-2025 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $119.16 | 2023-2025 | Jardiance, Ofev |
| Janssen Pharmaceuticals, INC | $110.57 | 2019-2024 | Xarelto |
| Abbott Laboratories | $107.26 | 2020-2025 | Freestyle Libre 3 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $101.67 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $80.35 | 2024-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $77.47 | 2019 | |
| Amarin Pharma, INC. | $63.86 | 2019-2021 | |
| Abbvie INC. | $62.06 | 2022-2023 | |
| Exact Sciences Corporation | $32.30 | 2024 | Cologuard Collection Kit |
| Allergan, INC. | $30.54 | 2020 | |
| Phadia US INC. | $25.46 | 2024 | Immunocap |
| Sumitomo Pharma America, INC. | $22.45 | 2025 | Gemtesa |
| Teva Pharmaceuticals USA, INC. | $22.08 | 2023 | Uzedy |
| Inspire Medical Systems, INC. | $18.49 | 2024 | Inspire |
| Catalyst Pharmaceuticals, INC. | $17.85 | 2024 | |
| Genentech USA, INC. | $16.90 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.09 | 2019 | |
| Insulet Corporation | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jorge Martinez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.